Guanylate-binding protein-1 is a potential new therapeutic target for triple-negative breast cancer.

ABSTRACT:

Background

Triple-negative breast cancer (TNBC) is characterized by a lack of estrogen and progesterone receptor expression (ESR and PGR, respectively) and an absence of human epithelial growth factor receptor (ERBB2) amplification. Approximately 15-20% of breast malignancies are TNBC. Patients with TNBC often have an unfavorable prognosis. In addition, TNBC represents an important clinical challenge since it does not respond to hormone therapy.

Methods

In this work, we integrated high-throughput mRNA sequencing (RNA-Seq) data from normal and tumor tissues (obtained from The Cancer Genome Atlas, TCGA) and cell lines obtained through in-house sequencing or available from the Gene Expression Omnibus (GEO) to generate a unified list of differentially expressed (DE) genes. Methy

SUBMITTER: Quintero M 

PROVIDER: S-EPMC5688804 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature